Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §3

AOD-PH2B-OBESITY — results

Primary endpoint, absolute and relative effect where derivable, and harms as reported.

Document identifier
CEI-TR-0108/3
Series
Trial abstract
Version
2.2
Published
05 Feb 2023
Last reviewed
05 Aug 2023
Next review
05 Aug 2025
Identifier
10.71829/cei.trial.108
Certainty
Not rated
Cycle
2023 Q1
Phase
Phase 2b
Status
Programme discontinued

§3Results

§3.1Primary endpoint

Table 3. Primary endpoint as reported.

EndpointResult as reportedCertainty
Percentage change in body weight from baseline to week 12No separation from placebo. Development in obesity was discontinuedNot rated
Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed.

§3.2Endpoint hierarchy

Categorical responder proportionsProportion of participants reaching each categorical response threshold, by arm.ThresholdAOD-9604Comparator≥ 5 % reduction88.7 %26.9 %≥ 10 % reduction64.3 %4.4 %≥ 15 % reduction29.3 %1.0 %≥ 20 % reduction8.7 %1.0 %
Figure 1. Illustrative. Categorical responder proportions derived by the Institute from the reported mean change under a logistic response model. These are not the published responder proportions for this trial. The figure is published because a mean conceals the distribution of response, and the shape of that distribution is what a reader most often wants and least often gets.

§3.3Harms as reported

Table 5. Adverse events for AOD-9604 from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.

EventActive, %Comparator, %Source trial
Injection-site reaction——Reported in research contexts
Headache——Reported
No effect on IGF-1——Consistently reported and consistent with the design intent
No effect on glucose tolerance——Consistently reported
Compound Evidence Institute · CEI-TR-0108/3 · https://compoundevidence.com/trials/aod-ph2b-obesity/results/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.